AZD-5672 is an orally active, potent, and selective CCR5 antagonist ( IC 50 =0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC 50 =7.3 μM). AZD5672 is a substrate of human P-gp , and inhibits P-gp-mediated digoxin transport (IC 50 =32 μM). AZD-5672 can be used for the research of rheumatoid arthritis In Vitro AZD-5672 (0, 0.1, 0.3, 1, 3, 10, 30, and 100 μM) inhibits P-gp-mediated digoxin transport in a concentration-dependent manner (mean apparent IC 50 : 32 μM) in Caco-2 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In vivo pharmaeokineties data for AZD-5672 (compound 1) Species CI a (mL/min/kg) V ss a (L/kg) t 1/2 a (h) F b (%) Rat 28 5.3 2.6 38 Dog 18 5.7 3.9 86 a AZD-5672 dosed 1-2 mg/kg i.v. b AZD-5672 dosed 2-5 mg/kg p.o. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CCR5|0.32 nM (IC|50|)|hERG|7.3 μM (IC|50|)|hP-gp|32 μM (IC|50|)